{"created":"2023-07-27T06:51:14.286966+00:00","id":44583,"links":{},"metadata":{"_buckets":{"deposit":"8850f6ac-3629-4f82-b299-4c7df9e0a023"},"_deposit":{"created_by":18,"id":"44583","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"44583"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00044583","sets":["2812:2813:2817"]},"author_link":["471","76666"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-06-12","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"4p.","bibliographicVolumeNumber":"2014-04-01 - 2017-03-31","bibliographic_titles":[{"bibliographic_title":"平成28(2016)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2016 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"希少疾病Lambert-Eaton筋無力症(LEMS)治療薬の3,4-diaminopyridine (3,4-DAP)について、我々が既に見出している「LEMS患者での3,4-DAPの血漿中濃度の速やかな消失に比べ薬効が持続する現象」のメカニズムの解明を目的として動物モデルおよび健常人について検討した。そして薬効と血漿中濃度動態にずれが生じる原因が、筋肉への高い移行性に起因していることが示唆された。これらの結果を確認するために、薬効の指標として、筋電位の変化を、α-bungarotoxinを投与して作成した筋無力症モデルを用いて検討し、先の結果を支持する知見を得た。","subitem_description_type":"Abstract"},{"subitem_description":"3,4-Diaminopyridine (3,4-DAP) is potassium channel inhibitor used to treat Lambert-Eaton myasthenic syndrome (LEMS). We investigated the pharmacokinetics of 3,4-DAP, which are still poorly understood, in rats and humans. In healthy Japanese volunteers, 3,4-DAP Vd/F and T1/2 were varied from 740 to 1669 L and from 35 to51 min, respectively. We found that 3,4-DAP was characterized by fast elimination from serum and high tissue perfusion in a dose-dependent manner. Furthermore, muscle mass was the inter-individual variability factor. In addition, studies in rat tissue distribution and compound muscle action potential with and without alpha-bungarotoxin indicated that 3,4-DAP response delay caused by high muscle distribution compared with plasma disposition.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:26460217, 研究期間(年度):2014-04-01 - 2017-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：「希少疾病LEMS治療薬3,4-ジアミノピリジン適正使用のための薬物動態学的検討」研究成果報告書　課題番号26460217\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26460217/26460217seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域薬学系","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00050924","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=20293368"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=20293368","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26460217/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26460217/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26460217/26460217seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-26460217/26460217seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-06-01"}],"displaytype":"detail","filename":"PH-PR-MATSUSHITA-R-kaken 2017-4p.pdf","filesize":[{"value":"111.5 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"PH-PR-MATSUSHITA-R-kaken 2017-4p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/44583/files/PH-PR-MATSUSHITA-R-kaken 2017-4p.pdf"},"version_id":"abe5fd72-d4a0-4e29-95c8-5ae672ec2b31"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"希少疾病LEMS治療薬3,4-ジアミノピリジン適正使用のための薬物動態学的検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"希少疾病LEMS治療薬3,4-ジアミノピリジン適正使用のための薬物動態学的検討"},{"subitem_title":"Phamacokinetic study of orphan drug 3,4-diaminopyridine fro treatment of Lambert-Eaton myasthenic syndrome","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2817"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-06-01"},"publish_date":"2018-06-01","publish_status":"0","recid":"44583","relation_version_is_last":true,"title":["希少疾病LEMS治療薬3,4-ジアミノピリジン適正使用のための薬物動態学的検討"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T11:36:03.861303+00:00"}